Reda G. Yousef

1.0k citations

41 papers · 875 indexed · h-index 17

Organic Chemistry top 5%
Molecular Biology
Toxicology top 1%
Computational Theory and Mathematics top 5%
Oncology

Co-authors: Ibrahim H. Eissa Ahmed M. Metwaly Eslam B. Elkaeed Hazem Elkady Dalal Z. Husein Ibrahim M. Ibrahim Ahmed B. M. Mehany Aisha A. Alsfouk
Topics: Bioactive Compounds and Antitumor Agents (20 papers)Synthesis and biological activity (15 papers)Angiogenesis and VEGF in Cancer (15 papers)
Cited by: Toxicology Organic Chemistry Computational Theory and Mathematics
Journals: PLoS ONE Molecules RSC Advances
Partner nations: Egypt Saudi Arabia United States

In The Last Decade

Reda G. Yousef

40 papers receiving 871 citations

Peers

Countries citing papers authored by Reda G. Yousef

Since Specialization

Citations

This map shows the geographic impact of Reda G. Yousef's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reda G. Yousef with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reda G. Yousef more than expected).

Fields of papers citing papers by Reda G. Yousef

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reda G. Yousef. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reda G. Yousef. The network helps show where Reda G. Yousef may publish in the future.

Co-authorship network of co-authors of Reda G. Yousef

This figure shows the co-authorship network connecting the top 25 collaborators of Reda G. Yousef. A scholar is included among the top collaborators of Reda G. Yousef based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reda G. Yousef. Reda G. Yousef is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	New nicotinamide–thiadiazol hybrids as VEGFR-2 inhibitors for breast cancer therapy: design, synthesis and in silico and in vitro evaluation 2025 ·RSC Advances ·Walid E. Elgammal,Hazem Elkady,Reda G. Yousef,Wagdy M. Eldehna,Dalal Z. Husein,(unknown),Bshra A. Alsfouk,Eslam B. Elkaeed,Ibrahim H. Eissa,Ahmed M. Metwaly	4
2	Development of novel furan-based VEGFR-2 inhibitors and apoptotic inducers for colorectal cancer 2025 ·Future Medicinal Chemistry ·Eslam B. Elkaeed,(unknown),Hazem Elkady,Reda G. Yousef,(unknown),(unknown),Esmail M. El‐Fakharany,Aisha A. Alsfouk,Ahmed M. Metwaly,Ibrahim H. Eissa	0
3	Discovery of new thieno[2,3-d]pyrimidine-based dual VEGFR-2 and EGFR inhibitors for enhanced therapeutic efficacy in breast cancer 2025 ·Journal of Molecular Structure ·Reda G. Yousef,Souad A. El‐Metwally,(unknown),Aisha A. Alsfouk,Dalal Z. Husein,(unknown),Eslam B. Elkaeed,Hazem Elkady,Ahmed M. Metwaly,Ibrahim H. Eissa	1
4	Integrated in silico and in vitro exploration of the anti-VEGFR-2 activities of a semisynthetic xanthine alkaloid inhibiting breast cancer 2025 ·PLoS ONE ·Eslam B. Elkaeed,Hazem Elkady,(unknown),Reda G. Yousef,Hanan Al-Ghulikah,Dalal Z. Husein,(unknown),Mohamed A. Elkady,Ahmed M. Metwaly,Ibrahim H. Eissa	1
5	Brain-derived neurotrophic factor (BDNF) Single nucleotide gene polymorphism and Nerve growth factor are risk factors that increase the severity of Allergic Rhinitis 2024 ·Egyptian Journal of Chemistry ·(unknown),(unknown),(unknown),Reda G. Yousef	1
6	Design and In Silico and In Vitro Evaluations of a Novel Nicotinamide Derivative as a VEGFR-2 Inhibitor 2024 ·Journal of Chemistry ·Ibrahim H. Eissa,(unknown),Reda G. Yousef,Hazem Elkady,Eslam B. Elkaeed,Bshra A. Alsfouk,Ibrahim M. Ibrahim,Ahmed M. Metwaly,Dalal Z. Husein	2
7	Beta Catenin Expression in Colorectal Carcinoma and its relation to survival and prognostic factors 2024 ·Annals of Cancer Research and Therapy ·(unknown),Tareq Saleh,(unknown),(unknown),Reda G. Yousef,(unknown),(unknown),(unknown)	3
8	Design and synthesis of new nicotinamides as immunomodulatory VEGFR-2 inhibitors and apoptosis inducers 2024 ·Future Medicinal Chemistry ·Reda G. Yousef,Ibrahim H. Eissa,Hazem Elkady,Taha Mehany,(unknown),Mohamed M. Radwan,Mahmoud A. ElSohly,(unknown),Alaa Elwan,Mohamed Ayman El‐Zahabi	4
9	A Theobromine Derivative with Anticancer Properties Targeting VEGFR‐2: Semisynthesis, in silico and in vitro Studies 2023 ·ChemistryOpen ·Ibrahim H. Eissa,Reda G. Yousef,Hazem Elkady,Eslam B. Elkaeed,Aisha A. Alsfouk,Dalal Z. Husein,Ibrahim M. Ibrahim,Mohamed M. Radwan,Ahmed M. Metwaly	11
10	Design, Molecular Modeling, MD Simulations, Essential Dynamics, ADMET, DFT,Synthesis, Anti-proliferative, and Apoptotic Evaluations of a New Anti-VEGFR-2Nicotinamide Analogue 2023 ·Current Pharmaceutical Design ·Ibrahim H. Eissa,Eslam B. Elkaeed,Hazem Elkady,Reda G. Yousef,Bshra A. Alsfouk,Heba S. A. Elzahabi,Ibrahim M. Ibrahim,Ahmed M. Metwaly,Dalal Z. Husein	2
11	New theobromine derivative as apoptotic anti-triple-negative breast cancer targeting EGFR protein: CADD story 2023 ·Journal of Molecular Structure ·Ibrahim H. Eissa,Reda G. Yousef,Hazem Elkady,Eslam B. Elkaeed,Dalal Z. Husein,Ibrahim M. Ibrahim,Bshra A. Alsfouk,Ahmed S. Doghish,Hesham A. El‐Mahdy,Ahmed M. Kenawy,Nehal M. El‐Deeb,Ahmed M. Metwaly	36
12	New apoptotic anti-triple-negative breast cancer theobromine derivative inhibiting EGFRWT and EGFRT790M: in silico and in vitro evaluation 2023 ·Molecular Diversity ·Ibrahim H. Eissa,Reda G. Yousef,Hazem Elkady,Aisha A. Alsfouk,Dalal Z. Husein,Ibrahim M. Ibrahim,Nehal M. El‐Deeb,Ahmed M. Kenawy,Wagdy M. Eldehna,Eslam B. Elkaeed,Ahmed M. Metwaly	13
13	Design, semi-synthesis, anti-cancer assessment, docking, MD simulation, and DFT studies of novel theobromine-based derivatives as VEGFR-2 inhibitors and apoptosis inducers 2023 ·Computational Biology and Chemistry ·Ibrahim H. Eissa,Reda G. Yousef,Hazem Elkady,Eslam B. Elkaeed,Aisha A. Alsfouk,Dalal Z. Husein,Ibrahim M. Ibrahim,Mostafa A. Elhendawy,(unknown),Ahmed M. Metwaly	34
14	Anti-breast cancer potential of a new xanthine derivative: In silico, antiproliferative, selectivity, VEGFR-2 inhibition, apoptosis induction and migration inhibition studies 2023 ·Pathology - Research and Practice ·Ibrahim H. Eissa,Reda G. Yousef,Hazem Elkady,Eslam B. Elkaeed,Bshra A. Alsfouk,Dalal Z. Husein,(unknown),Ibrahim M. Ibrahim,Ahmed M. Metwaly	14
15	Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2 2023 ·Saudi Pharmaceutical Journal ·Ibrahim H. Eissa,Reda G. Yousef,(unknown),Hazem Elkady,Dalal Z. Husein,Aisha A. Alsfouk,Ibrahim M. Ibrahim,Mohamed A. Elkady,Eslam B. Elkaeed,Ahmed M. Metwaly	12
16	Discovery of New VEGFR-2 Inhibitors: Design, Synthesis, Anti-Proliferative Evaluation, Docking, and MD Simulation Studies 2022 ·Molecules ·Eslam B. Elkaeed,Reda G. Yousef,Mohamed M. Khalifa,(unknown),Ahmed B. M. Mehany,(unknown),Bshra A. Alsfouk,Wagdy M. Eldehna,Ahmed M. Metwaly,Ibrahim H. Eissa,Mohamed Ayman El‐Zahabi	33
17	Discovery of new nicotinamides as apoptotic VEGFR-2 inhibitors: virtual screening, synthesis, anti-proliferative, immunomodulatory, ADMET, toxicity, and molecular dynamic simulation studies 2022 ·Journal of Enzyme Inhibition and Medicinal Chemistry ·Reda G. Yousef,(unknown),Mohamed M. Khalifa,Wagdy M. Eldehna,(unknown),Ahmed B. M. Mehany,Eslam B. Elkaeed,Aisha A. Alsfouk,Ahmed M. Metwaly,Ibrahim H. Eissa	45
18	Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2 2022 ·Molecules ·Reda G. Yousef,Wagdy M. Eldehna,Alaa Elwan,(unknown),Ahmed B. M. Mehany,(unknown),Bshra A. Alsfouk,Eslam B. Elkaeed,Ahmed M. Metwaly,Ibrahim H. Eissa	17
19	Inhibition of Vascular Smooth Muscle and Cancer Cell Proliferation by New VEGFR Inhibitors and Their Immunomodulator Effect: Design, Synthesis, and Biological Evaluation 2021 ·Oxidative Medicine and Cellular Longevity ·Feng Ran,Wendong Li,Yi Qin,Tong Yu,(unknown),Min Zhou,Cheng Liu,Tong Qiao,Xiaoqiang Li,Reda G. Yousef,Ibrahim H. Eissa,Mohamed M. Khalifa	31
20	Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation 2021 ·Bioorganic Chemistry ·Khaled El‐Adl,Helmy Sakr,Reda G. Yousef,Ahmed B. M. Mehany,Ahmed M. Metwaly,Mostafa A. Elhendawy,Mohamed M. Radwan,Mahmoud A. ElSohly,Hamada S. Abulkhair,Ibrahim H. Eissa	93

About Reda G. Yousef

Reda G. Yousef is a scholar working on Toxicology, Computational Theory and Mathematics and Organic Chemistry, having authored 41 papers that have together received 875 indexed citations. Recurring topics across this work include Bioactive Compounds and Antitumor Agents (20 papers), Synthesis and biological activity (15 papers) and Angiogenesis and VEGF in Cancer (15 papers). The work is most often cited by research in Toxicology (198 citations), Organic Chemistry (533 citations) and Computational Theory and Mathematics (167 citations). Reda G. Yousef has collaborated with scholars based in Egypt, Saudi Arabia and United States. Frequent co-authors include Ibrahim H. Eissa, Ahmed M. Metwaly, Eslam B. Elkaeed, Hazem Elkady, Dalal Z. Husein, Ibrahim M. Ibrahim, Ahmed B. M. Mehany, Aisha A. Alsfouk, Bshra A. Alsfouk and Mostafa A. Elhendawy. Their work appears in journals such as PLoS ONE, Molecules and RSC Advances.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact